Forskning
Udskriv Udskriv
Switch language
Rigshospitalet - en del af Københavns Universitetshospital
E-pub ahead of print

Haloperidol for the treatment of delirium in critically ill patients: a systematic review with meta-analysis and Trial Sequential Analysis

Publikation: Bidrag til tidsskriftReviewForskningpeer review

DOI

  1. External validation of the Simplified Mortality Score for the Intensive Care Unit (SMS-ICU)

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Lower vs higher transfusion threshold in septic shock patients of different ages: A study protocol

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Performance of SAPS II according to ICU length of stay: A Danish nationwide cohort study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Effects of simulated sample sizes on mortality estimates-Protocol for a study in 3 randomised ICU trials

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. DEBATE-statistical analysis plans for observational studies

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Antibiotic regimens for neonatal sepsis - a protocol for a systematic review with meta-analysis

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

BACKGROUND: Haloperidol is the most frequently used drug to treat delirium in the critically ill patients. Yet, no systematic review has focussed on the effects of haloperidol in critically ill patients with delirium.

METHODS: We conducted a systematic review with meta-analysis and Trial Sequential Analysis of randomised clinical trials (RCTs) assessing the effects of haloperidol versus any intervention on all-cause mortality, serious adverse reactions/events, days alive without delirium, health-related quality of life (HRQoL), cognitive function and delirium severity in critically ill patients with delirium. We also report on QTc prolongation, delirium resolution and extrapyramidal symptoms.

RESULTS: We included 8 RCTs with 11 comparisons (n=951). We adjudicated one trial as having overall low risk of bias. Three trials used rescue haloperidol; excluding these, we did not find an effect of haloperidol versus control on all-cause mortality (RR 1.01; 95% CI 0.33-3.06; I2 =0%; 112 participants; 3 trials; 4 comparisons; very low certainty) or delirium severity (SMD -0.15; 95% CI -0.61-0.30; I2 =27%; 134 participants; 3 trials; 4 comparisons; very low certainty). No trials reported adequately on serious adverse reactions/events. Only one trial reported on days alive without delirium, cognitive function and QTc prolongation, and no trials reported on HRQoL. Sensitivity analyses, including trials using rescue haloperidol, did not change the results.

CONCLUSIONS: The evidence for the use of haloperidol to treat critically ill patients with delirium is sparse, of low quality, and inconclusive. We therefore have no certainty regarding any beneficial, harmful or neutral effects of haloperidol in these patients.

OriginalsprogEngelsk
TidsskriftActa Anaesthesiologica Scandinavica
ISSN0001-5172
DOI
StatusE-pub ahead of print - 29 okt. 2019

Bibliografisk note

© 2019 The Acta Anaesthesiologica Scandinavica Foundation. Published by John Wiley & Sons Ltd.

ID: 58261819